Healing Influence of Melilotus Offcinalis Herbal Extract on Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice

Document Type : Research article

Authors

1 Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

2 Department of Basic Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

3 School of Medicine, AJA University of Medical Science, Tehran, Iran.

Abstract

The present study was designed to primarily examine the therapeutic potential of the herbal extract of Melilotus Offcinalis for the treatment of multiple sclerosis in the experimental autoimmune encephalomyelitis (EAE) model of the disease. The animal model was induced in C57BL/6 female mice, and then the herbal extract was intraperitoneally administered for a total of 21 days after the frst day of post-immunization. The phenotypic signs, a gene expression profle of inflammatory cytokines, antioxidant state, and pathological hallmarks of the disease in the corpus callosum were evaluated. The prophylactic administration of Melilotus Offcinalis attenuates the clinical signs of the disease. It signifcantly declined the gene expression of proinflammatory cytokines like IL-6, TNF-α, and IFN-γ. This herbal extract also surged the gene expression, as an anti-inflammatory cytokine. The gene expression of Glutathione peroxidase and Catalase (antioxidant enzymes) was meaningfully higher in the treatment group. Pathological evaluation of corpus callosum cross-sections by Luxol Fast Blue staining revealed preserved myelin sheath in the treated group compared to the EAE mice. The results of our assay confrmed that immunomodulatory and antioxidant features of the herbal extract of Melilotus Offcinalis ameliorated the EAE  severity. This study fnding disclosed the therapeutic effciency of this compound in MS treatment.

Graphical Abstract

Healing Influence of Melilotus Offcinalis Herbal Extract on Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice

Keywords


(1)          Goldenberg MM. Multiple sclerosis review. Pharm. Therapeut. (2012) 37: 175-84
(2)          Trapp BD and Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. (2008) 31: 247-69.
(3)          Alfredsson L and Olsson T. Lifestyle and environmental factors in multiple sclerosis. CSH. Perspect. Med. (2019) 9: a028944.
(4)          Gourraud PA, Harbo HF, Hauser SL and Baranzini SE. The genetics of multiple sclerosis: an up‐to‐date review. Immunol. Rev. (2012) 248: 87-103.
(5)          Palle P, Monaghan KL, Milne SM and Wan EC. Cytokine signaling in multiple sclerosis and its therapeutic applications. Med. Sci. (2017) 5: 23.
(6)          Nicholson LB and Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr. opin. immunol. (1996) 8: 837-42.
(7)          Lim S and Constantinescu C. Current and future disease‐modifying therapies in multiple sclerosis. Int. J. clin. pract. (2010) 64: 637-50.
(8)          Mojaverrostami S, Bojnordi MN, Ghasemi Kasman M, Ebrahimzadeh MA and Hamidabadi HG. A Review of herbal therapy in multiple sclerosis. Advan. Pharm. Bull. (2018) 8: 575-90
(9)          Solanki I, Parihar P and Parihar MS. Neurodegenerative diseases: from available treatments to prospective herbal therapy. Neurochem. Int. (2016) 95: 100-8.
(10)        Pleşca‐Manea L, Pârvu AE, Parvu M, Taaˇmaş M, Buia R and Puia M. Effects of Melilotus officinalis on acute inflammation. Phytother. Res. (2002) 16: 316-9.
(11)        Chorepsima S, Tentolouris K, Dimitroulis D and Tentolouris N. Melilotus: Contribution to wound healing in the diabetic foot. J. Herb. Med. (2013) 3: 81-6.
(12)        Larijani B, Heshmat R, Bahrami A, Delshad H, Mohammad K, Heidarpour R, Mohajeri Tehrani MR, Kamali K, Farhadi M and Gharibdoust f. Effects of intravenous Semelil (ANGIPARSTM) on diabetic foot ulcers healing: A multicenter clinical trial. Daru J. Pharm. Sci. (2008) 16: 35-40.
(13)        Abdollahi M, Farzamfar B, Salari P, Khoram KH, Farhadi M and Madani S. Evaluation of acute and sub-chronic toxicity of semelil (ANGIPARS™), a new phytotherapeut. drug wound Heal. in Rod. (2008) 16: 7-14.
(14)        Ebrahimi M, Bakhshayeshi S, Heshmat R, Shahbazi S, Aala M, Peimani M, Khushechin G, Mohajeri Tehrani MR, Shojaeefard A and Kamali K. Post marketing surveillance on safety and effectiveness of ANGIPARS in treatment of diabetic foot ulcers. Daru J. Pharma. Sci. (2015) 1: 45-49.
(15)        Farzamfar B, Abdollahi M, Kabinezhadian S, Heshmat R, Shah HMH, Novitsky Y and Farhadi M. Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs. Daru J. Pharma. Sci. (2008). 16: 15-19
(16)        Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salari P, Farzamfar B and Madani SH. In-vivo and in-vitro genotoxicity studies of Semelil (ANGIPARSTM). Daru J. Pharm. Sci. (2008) 16: 20-4.
(17)        Ghanbari S, Yonessi M, Mohammadirad A, Gholami M, Baeeri M, Khorram Khorshid HR, Gharibdoost F and Abdollahi M. Effects of IMOD™ and Angipars™ on mouse D-galactose-induced model of aging. Daru J. Pharm. Sci. (2012) 20: 1-68.
(18)        Mardiguian S, Serres S, Ladds E, Campbell SJ, Wilainam P, McFadyen C, McAteer M, Choudhury RP, Smith P and Saunders F. Anti–IL-17A treatment reduces clinical score and VCAM-1 expression detected by in-vivo magnetic resonance imaging in chronic relapsing EAE ABH mice. Am. J.Pathol. (2013) 182: 2071-81.
(19)        Moudgil KD and Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J. Interferon Cytokine Res. (2011) 31: 695-703.
(20)        Selmaj KW, editor The role of cytokines in inflammatory conditions of the central nervous system. Semi. Neurosci.; (1992): 4: 221-229.
(21)        Irani DN. Immunological mechanisms in multiple sclerosis. Clin. App. Immunol. Rev. (2005) 5: 257-69.
(22)        Kuwabara T, Ishikawa F, Kondo M and Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm (2017).
(23)        Dudek I, Zagorski T, Liskiewicz J, Kedziora J and Chmielewski H. Effect of gamma radiation on selected indicators of oxygen metabolism in erythrocytes of patients with multiple sclerosis. Neurologia i Neurochirurgia Polska. (1992) 26: 34-9.
(24)        Zhao G-c, Yuan Y-l, Chai F-r and Ji F-j. Effect of Melilotus officinalis extract on the apoptosis of brain tissues by altering cerebral thrombosis and inflammatory mediators in acute cerebral ischemia. Biomed. Pharm. (2017) 89: 1346-52.
(25)        Zangiabadi N, Mohtashami H, Hojatipour M, Jafari M, Asadi-Shekaari M and Shabani M. The effect of Angipars on diabetic neuropathy in STZ-induced diabetic male rats: a study on behavioral, electrophysiological, sciatic histological and ultrastructural indices. Sci. World J. (2014).
(26)        Hong N, Won D and Kim N. Pharmacological Studies on Melilotus officinalis Extract. Kor. J. Pharm. (1983) 14: 51-9.
(27)        Liu MW, Su MX, Wang YH and Qian CY. Effect of Melilotus extract on lung injury via the upregulation of tumor necrosis factor-α-induced protein-8-like 2 in septic mice. Mol. Med. Rep. (2015) 11: 1675-84.
(28)        Liu Y-T, Gong P-H, Xiao F-Q, Shao S, Zhao D-Q, Yan M-M and Yang XW. Chemical Constituents and Antioxidant, Anti-Inflammatory and Anti-Tumor Activities of Melilotus officinalis (Linn.) Pall. Mol. (2018) 23: 271.
(29)        Sheikh N, Desai T and Tirgar P. Investigation into iron chelating and antioxidant potential of Melilotus officinalis in iron dextran induced iron overloaded Sprague Dawley rat model. Drug Res. (2016) 66: 618-27.